The device has not yet been approved by the U . S . Food and Drug Administration . In June the agency issued a draft guidance seeking input from the industry and researchers on an early version of the artificial pancreas , called the low glucose suspend system . It ' s a backup for diabetics experiencing hypoglycemia . Patients still have to monitor their levels and give themselves insulin if necessary , but the low glucose suspend system temporarily reduces or stops the insulin flow in the event of an episode .
